Could a single pill replace two for diabetes?
NCT ID NCT07538466
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial will test a new tablet called AD-123 in 50 healthy adults. Researchers want to see if taking one AD-123 pill works similarly to taking two separate pills (AD-1231 and AD-1232) together. The study focuses on safety and how the drug moves through the body, not on treating diabetes itself.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AD-123 (oral tablet) and combination of AD-1231 and AD-1232 (oral tablets)
What this could lead to
If successful, this study could show that a single tablet (AD-123) works as well as taking two separate tablets, potentially simplifying diabetes treatment.
What could go wrong
This is a very early Phase 1 trial in only 50 healthy volunteers, not people with diabetes. It only measures safety and drug levels, not whether the drug actually helps control diabetes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
H Plus Yangji Hospita
Seoul, South Korea